• Change from baseline in total non-inflammatory lesions. [ Time Frame: Baseline, Weeks 2, 4, 6, 8, 10 and12 ] [ Designated as safety issue: No ]
  

• Change from baseline and percent change from baseline in each lesion type [ Time Frame: Baseline, Weeks 2, 4, 6, 8, 10 and12 ] [ Designated as safety issue: No ]
  
• Change from baseline for each visit in Investigator's Global Assessment of Acne Severity (IGA #1 and IGA #2) score [ Time Frame: Baseline, Weeks 2, 4, 6, 8, 10 and12 ] [ Designated as safety issue: No ]
  
• Measurement of success according to dichotomized IGA scores (IGA #1 And IGA #2) using criteria of improvement of 2 grades from baseline score or clear or almost clear grades (grades 0 or 1) [ Time Frame: Baseline, Weeks 2, 4, 6, 8, 10 and12 ] [ Designated as safety issue: No ]
  
• Improvement from baseline in Investigator Global Assessment score (IGA # 3) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  

Approximately 100 female and male subjects, aged from 9 to 11 years of age, will be enrolled in this randomized, double blind, multi-center study.

Following satisfaction of entry criteria and screening procedures, subjects will receive either RETIN-A MICRO 0.04% or a color matched gel vehicle for once daily use during the 12-week treatment period. Subjects will be monitored for safety throughout the study and for signs and symptoms of local irritation at baseline, and at weeks 2, 4, 6, 8, 10 and again at study completion, week 12.

Efficacy will be assessed by facial lesion counts and by utilizing scales for Investigator's Global Evaluation of Acne Severity (IGA #1 and IGA #2) and Investigator's Global Assessment of Improvement (IGA #3). All efficacy parameters with the exception of IGA #3 will be measured at baseline and weeks 2, 4, 6, 8, 10 and 12. The Investigator's Global Assessment of Improvement (IGA #3) will be done at Week 12 only. At selected sites, photographs will be taken at Baseline and weeks 2, 4, 8 and 12.